The US Food and Drug Administration has approved a generic version of Pfizer’s Neurontin Tablets to treat postherpetic neuralgia.

The abbreviated new drug application will allow Mylan Pharmaceuticals to distribute the generic treatment, known as Gabapentin, in 600mg and 800mg tablets.

Neurontin had sales of $174m during the 12-month period ending 31 March.

Postherpetic neuralgia is a persistent pain condition caused by nerve damage after a shingles infection.